The American College of Physicians (ACP) issued updated vaccine practice points for physicians that advise adults aged 75 or older should receive a protein subunit Respiratory Syncytial Virus (RSV) ...

Vaccine effectiveness also dropped from 75.2% to 39.7% among immunocompromised individuals. Authors note that the RSV vaccine is still effective, but older and immunocompromised individuals may ...

RSV vaccines showed initial high effectiveness, but protection decreased over 18 months, especially in immunocompromised individuals. The study used VHA data to evaluate vaccine effectiveness in ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock. At ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. Susan Green developed a stubborn ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) vaccine, a new study finds. The report also showed that people in long-term ...

Maternal respiratory syncytial virus vaccination appeared to be safe and effective for mothers with HIV and their infants, ...

Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for ...

Data shows that ER visits and hospital admissions for RSV have been climbing in New Jersey since early October. Currently, ER ...